Drug Profile
GALE 301
Alternative Names: E39 peptide vaccine; E39+GM-CSF vaccine; FBP-E39; Folate Binding Protein-E39 vaccine; GALE-301Latest Information Update: 08 Jun 2021
Price :
$50
*
At a glance
- Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; University of Texas M. D. Anderson Cancer Center
- Developer Sellas Life Sciences Group; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Protein vaccines
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Endometrial cancer; Ovarian cancer
Most Recent Events
- 31 Mar 2021 Sellas Life Sciences terminates its licence for folate binding protein-E39 targeted cancer vaccine in February 2021
- 01 Dec 2019 Discontinued - Phase-I/II for Breast cancer (Prevention of relapse) in USA (Intradermal) (3464169; 9287650)
- 01 Dec 2019 Discontinued - Phase-II for Endometrial cancer (Prevention of relapse, Adjuvant therapy) in USA (Intradermal) (3464169; 9287650)